1. Home
  2. SOC vs TOVX Comparison

SOC vs TOVX Comparison

Compare SOC & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SOC
  • TOVX
  • Stock Information
  • Founded
  • SOC 2020
  • TOVX 2001
  • Country
  • SOC United States
  • TOVX United States
  • Employees
  • SOC N/A
  • TOVX N/A
  • Industry
  • SOC
  • TOVX Biotechnology: Pharmaceutical Preparations
  • Sector
  • SOC
  • TOVX Health Care
  • Exchange
  • SOC Nasdaq
  • TOVX Nasdaq
  • Market Cap
  • SOC 2.8B
  • TOVX 4.5M
  • IPO Year
  • SOC N/A
  • TOVX 2006
  • Fundamental
  • Price
  • SOC $22.61
  • TOVX $0.41
  • Analyst Decision
  • SOC Buy
  • TOVX Hold
  • Analyst Count
  • SOC 3
  • TOVX 1
  • Target Price
  • SOC $30.00
  • TOVX N/A
  • AVG Volume (30 Days)
  • SOC 3.9M
  • TOVX 1.0M
  • Earning Date
  • SOC 11-13-2025
  • TOVX 11-11-2025
  • Dividend Yield
  • SOC N/A
  • TOVX N/A
  • EPS Growth
  • SOC N/A
  • TOVX N/A
  • EPS
  • SOC N/A
  • TOVX N/A
  • Revenue
  • SOC N/A
  • TOVX N/A
  • Revenue This Year
  • SOC N/A
  • TOVX N/A
  • Revenue Next Year
  • SOC $184.34
  • TOVX N/A
  • P/E Ratio
  • SOC N/A
  • TOVX N/A
  • Revenue Growth
  • SOC N/A
  • TOVX N/A
  • 52 Week Low
  • SOC $16.26
  • TOVX $0.37
  • 52 Week High
  • SOC $35.00
  • TOVX $4.29
  • Technical
  • Relative Strength Index (RSI)
  • SOC 41.51
  • TOVX 51.10
  • Support Level
  • SOC $21.75
  • TOVX N/A
  • Resistance Level
  • SOC $24.48
  • TOVX $0.45
  • Average True Range (ATR)
  • SOC 1.83
  • TOVX 0.02
  • MACD
  • SOC -0.23
  • TOVX -0.01
  • Stochastic Oscillator
  • SOC 41.00
  • TOVX 91.67

About SOC Sable Offshore Corp. Common Stock

Sable Offshore Corp is a Houston-based independent upstream company focused on responsibly developing the prolific Santa Ynez Unit in federal waters offshore California. The company is managed as one reportable segment, oil and gas.

About TOVX Theriva Biologics Inc.

Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.

Share on Social Networks: